| Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis M Baz, Y Abed, J Papenburg, X Bouhy, MÈ Hamelin, G Boivin New England Journal of Medicine 361 (23), 2296-2297, 2009 | 519 | 2009 |
| Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform J Denis, E Acosta-Ramirez, Y Zhao, ME Hamelin, I Koukavica, M Baz, ... Vaccine 26 (27-28), 3395-3403, 2008 | 244 | 2008 |
| Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child M Baz, Y Abed, J McDonald, G Boivin Clinical infectious diseases 43 (12), 1555-1561, 2006 | 219 | 2006 |
| Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds Y Abed, M Baz, G Boivin Antiviral therapy 11 (8), 971-976, 2006 | 203 | 2006 |
| Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections J Papenburg, M Baz, MÈ Hamelin, C Rhéaume, J Carbonneau, M Ouakki, ... Clinical Infectious Diseases 51 (9), 1033-1041, 2010 | 138 | 2010 |
| Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A (H1N1) viruses M Baz, Y Abed, P Simon, ME Hamelin, G Boivin The Journal of infectious diseases 201 (5), 740-745, 2010 | 137 | 2010 |
| H5N1 vaccines in humans M Baz, CJ Luke, X Cheng, H Jin, K Subbarao Virus research 178 (1), 78-98, 2013 | 110 | 2013 |
| Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets ME Hamelin, M Baz, Y Abed, C Couture, P Joubert, E Beaulieu, ... PLoS pathogens 6 (7), e1001015, 2010 | 100 | 2010 |
| Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir M Baz, Y Abed, G Boivin Antiviral research 74 (2), 159-162, 2007 | 84 | 2007 |
| Antiviral agents in development for Zika virus infections M Baz, G Boivin Pharmaceuticals 12 (3), 101, 2019 | 83 | 2019 |
| Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes Y Abed, B Nehmé, M Baz, G Boivin Antiviral research 77 (2), 163-166, 2008 | 75 | 2008 |
| Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets Z Chen, M Baz, J Lu, M Paskel, C Santos, K Subbarao, H Jin, Y Matsuoka Journal of virology 88 (12), 7016-7023, 2014 | 67 | 2014 |
| Impact of the baloxavir-resistant polymerase acid I38T substitution on the fitness of contemporary influenza A (H1N1) pdm09 and A (H3N2) strains L Checkmahomed, Z M’hamdi, J Carbonneau, MC Venable, M Baz, ... The Journal of infectious diseases 221 (1), 63-70, 2020 | 61 | 2020 |
| Structural insight into NS5 of Zika virus leading to the discovery of MTase inhibitors P Stephen, M Baz, G Boivin, SX Lin Journal of the American Chemical Society 138 (50), 16212-16215, 2016 | 57 | 2016 |
| Infections by human coronavirus-NL in hospitalized children G Boivin, M Baz, S Côté, R Gilca, C Deffrasnes, É Leblanc, MG Bergeron, ... The Pediatric infectious disease journal 24 (12), 1045-1048, 2005 | 57 | 2005 |
| Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge M Baz, K Boonnak, M Paskel, C Santos, T Powell, A Townsend, ... MBio 6 (5), 10.1128/mbio. 01487-15, 2015 | 55 | 2015 |
| Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza … M Baz, M Samant, H Zekki, P Tribout-Jover, M Plante, AM Lanteigne, ... Clinical and Vaccine Immunology 19 (2), 209-218, 2012 | 51 | 2012 |
| A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus Y Abed, M Baz, G Boivin The Journal of infectious diseases 199 (2), 180-183, 2009 | 48 | 2009 |
| Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients CL Tremblay, D Rouleau, C Fortin, E Toma, M Sylla, L Cyr, S Cote, M Baz, ... Vaccine 29 (7), 1359-1363, 2011 | 36 | 2011 |
| Replication and immunogenicity of swine, equine, and avian H3 subtype influenza viruses in mice and ferrets M Baz, M Paskel, Y Matsuoka, J Zengel, X Cheng, H Jin, K Subbarao Journal of virology 87 (12), 6901-6910, 2013 | 32 | 2013 |
